Gastrointestinal Cancer News

Distance caregivers of patients with cancer reported significant reductions in anxiety and distress after completing a series of coaching sessions via videoconference, according to study results scheduled for presentation during the ASCO20 Virtual Scientific Program.

Atezolizumab in combination with bevacizumab improved OS and PFS compared with sorafenib among patients with unresectable hepatocellular carcinoma, according to results of the randomized phase 3 IMbrave150 study published in The New England Journal of Medicine.

The FDA granted fast track designation to several therapies in development for hematology or oncology indications.

The FDA granted breakthrough therapy designation to fam-trastuzumab deruxtecan-nxki for treatment of patients with HER2-positive unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

Circulating tumor DNA has shown great promise as a blood-based, prognostic biomarker for patients with colon cancer, with detectable levels after resection considered an indicator of elevated risk for recurrence.

The FDA granted orphan drug designation to MIV-818 for the treatment of hepatocellular carcinoma.

Larotrectinib appeared highly effective for adults and children with tropomyosin receptor kinase fusion cancers, according to study results presented at the virtual American Association for Cancer Research Annual Meeting.

Atezolizumab plus cobimetinib significantly prolonged PFS compared with atezolizumab alone among a cohort of patients with advanced biliary tract cancer, according to results of a phase 2 study presented at the virtual American Association for Cancer Research Annual Meeting.

The FDA approved an additional recommended dosage of pembrolizumab, authorizing its use at 400 mg every 6 weeks.

A cell-free DNA multicancer early detection test demonstrated an ability to predict cancer and the tissue of origin in individuals with clinical suspicion of cancer, according to results of the Circulating Cell-free Genome Atlas study presented at the virtual American Association for Cancer Research Annual Meeting.